Evidence map›Paper›PMID 32021089›Full record

ArticleDrug design, development and therapy2020

Engineering of Naproxen Loaded Polymer Hybrid Enteric Microspheres for Modified Release Tablets: Development, Characterization, in silico Modelling and in vivo Evaluation.

Hajra Afeera Hameed, Shahzeb Khan, Muhammad Shahid, Riaz Ullah, Ahmed Bari, Syed Saeed Ali, Zahid Hussain, Muhammad Sohail, Shafi Ullah Khan, Thet Thet Htar

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Nanobiotechnologies for stroke treatment.Nanomedicine (London, England) · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 6 countries.

Hajra Afeera HameedDepartment of Pharmacy, University of Malakand, Chakdara, Khyber Pakhtunkhwa 18800, Pakistan.
Shahzeb KhanDepartment of Pharmacy, University of Malakand, Chakdara, Khyber Pakhtunkhwa 18800, Pakistan.ORCID 0000-0002-3464-5435
Muhammad ShahidDepartment of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Khyber Pakhtunkhwa, Pakistan.ORCID 0000-0002-6953-7848
Riaz UllahMedicinal, Aromatic & Poisonous Plants Research Center (MAPPRC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Ahmed BariCentral Laboratory, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Syed Saeed AliCentral Laboratory, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Zahid HussainDepartment of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0002-6978-3133
Muhammad SohailDepartment of Pharmacy, COMSATS University Islamabad, Abbottabad 22060, Pakistan.ORCID 0000-0003-3596-1760
Shafi Ullah KhanSchool of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya 47500, Malaysia.
Thet Thet HtarSchool of Pharmacy, Monash University Malaysia, Bandar Sunway, Subang Jaya 47500, Malaysia.ORCID 0000-0001-6193-1237
King Saud University · SAMonash University Malaysia · MYCOMSATS University Islamabad · PKSarhad University of Science and Information Technology · PKUniversity of Malakand · PKUniversity of Sharjah · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNaproxen (NP) is a non-steroidal anti-inflammatory drug with poor aqueous solubility and low oral bioavailability, which may lead to therapeutic failure. NP causes crucial GIT irritation, bleeding, and peptic and duodenal ulcers. PURPOSE OF THE STUDY: This study aimed to engineer and characterize polymer hybrid enteric microspheres using an integrated (experimental and molecular modelling) approach with further development to solid dosage form with modified drug release kinetics and improved bioavailability. MATERIALS AND

methodsNP loaded polymer hybrid enteric microspheres (PHE-Ms) were fabricated by using a modified solvent evaporation technique coupled with molecular modelling (MM) approach. The PHE-Ms were characterized by particle size, distribution, morphology, crystallinity, EE, drug-polymer compatibility, and DSC. The optimized NP loaded PHE-Ms were further subjected to downstream procedures including tablet dosage form development, stability studies and comparative in vitro-in vivo evaluation.

resultsThe hydrophobic polymer EUD-L100 and hydrophilic polymer HPMC-E5 delayed and modified drug release at intestinal pH while imparting retardation of NP release at gastric pH to diminish the gastric side effects. The crystallinity of the NP loaded PHE-Ms was established through DSC and P (XRD). The particle size for the developed formulations of PEH-Ms (M1-M5) was in the range from 29.06 ±7.3-74.31 ± 17.7 μm with Span index values of 0.491-0.69, respectively. The produced NP hybrid microspheres demonstrated retarded drug release at pH 1.2 and improved dissolution at pH 6.8. The in vitro drug release patterns were fitted to various release kinetic models and the best-followed model was the Higuchi model with a release exponent "n" value > 0.5. Stability studies at different storage conditions confirmed stability of the NP loaded PHE-Ms based tablets (

conclusionThe current study concludes that developing NP loaded PHE-Ms based tablets could effectively reduce GIT consequences with restored therapeutic effects. The modified release pattern could improve the dissolution rate and enhancement of oral bioavailability. The MM study strengthens the polymer-drug relationship in microspheres.

Indexed as

MicrospheresComputer SimulationDrug CompoundingDrug Delivery SystemsDrug LiberationDrug StabilityModels, MolecularNaproxenPolymersTabletsNaproxenPolymersTabletsbioavailabilitydissolutionhybrid microspheresmodified-release tabletsmolecular modellingnaproxen

Identifiers

PMID32021089
PMCPMC6954845
OpenAlexW2997840992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.